TC BioPharm Announces Pricing of $4 Million Underwritten Public Offering

Rhea-AI Summary

TC BioPharm (NASDAQ: TCBP) has announced the pricing of a public offering involving 10 million American Depositary Shares (ADSs) at $0.40 each, totaling $4 million in gross proceeds. The offering is set to close around June 7, 2022, pending customary conditions. The underwriters have a 45-day option to purchase an additional 1.5 million ADSs. The company specializes in developing gamma-delta T cell therapies for cancer treatment, with ongoing clinical trials and a strong intellectual property portfolio.

Positive

• Gross proceeds of $4 million from the offering to support continued development.
• Strengthening of pipeline with ongoing pivotal trials for cancer therapies.

Negative

• Potential shareholder dilution due to the issuance of new shares.
• Offering price may reflect current market challenges.

EDINBURGH, Scotland, June 2, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the pricing of an underwritten public offering of 10,000,000 American Depositary Shares (the "ADSs"), each ADS representing one ordinary share of the Company, at a public offering price of $0.40 per ADS, for aggregate gross proceeds of $4 million, prior to deducting underwriting discounts and commissions, and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 ADSs at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any.

The offering is expected to close on or about June 7, 2022, subject to satisfaction of customary closing conditions.

EF Hutton, division of Benchmark Investments, LLC, is acting as sole book-running manager for the offering.

A registration statement on Form F-1 (File No. 333-265159), was filed with the Securities and Exchange Commission ("SEC") and was declared effective on June [2], 2022. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. Electronic copies of the final prospectus relating to this offering, when available, may be obtained from EF Hutton, division of Benchmark Investments, LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@efhuttongroup.com or telephone at (212) 404-7002.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About TC BioPharm (Holdings) PLC

TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma delta t-cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.

TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia and Phase 1 trial for ImmuniStim in treatment of Covid patients using the Company's proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide. TC BioPharm also maintain a robust pipeline for future indication in solid tumors, as well as a significant IP/patent portfolio in the use of CARs with gamma delta t-cells and owns its own manufacturing facility to maintain cost and product quality controls.

Forward-Looking Statements

This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect our current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. We undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. The reference to the website of TC BioPharm has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-announces-pricing-of-4-million-underwritten-public-offering-301560649.html

SOURCE TC BioPharm

FAQ

What is the size of TC BioPharm's public offering?

TC BioPharm's public offering consists of 10 million American Depositary Shares, priced at $0.40 each, totaling $4 million.

When is TC BioPharm's offering expected to close?

The offering is expected to close around June 7, 2022.

What is the purpose of TC BioPharm's public offering?

The funds raised from the offering are intended to support the company's ongoing development of gamma-delta T cell therapies.

What is the impact of the offering on TC BioPharm shareholders?

The offering may lead to shareholder dilution due to the issuance of new ADSs.